UroGen Pharma (URGN) Non-Current Assets (2016 - 2026)
UroGen Pharma's (URGN) quarterly Non-Current Assets came in at $16.2 million in Q1 2026, up 55.41% YoY from $10.4 million in Q1 2025, and up 12.44% on a QoQ basis from $14.4 million in Q4 2025.
UroGen Pharma (URGN) Non-Current Assets (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Non-Current Assets data on file, last reported at $16.2 million in Q1 2026.
- Quarterly Non-Current Assets rose 55.41% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 million (up 98.38% YoY) and the FY2025 annual result came in at $14.4 million, up 50.7% from the prior year.
- Non-Current Assets grew to $16.2 million in Q1 2026, from $14.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $17.0 million in Q1 2023 to a low of $2.9 million in Q2 2024.
- A 5-year average of $10.0 million and a median of $9.6 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 79.46% — and 2025, when it soared 311.28%.
- Tracing URGN's Non-Current Assets over 5 years: stood at $6.7 million in 2022, then surged by 35.95% to $9.1 million in 2023, then gained by 4.94% to $9.6 million in 2024, then surged by 50.7% to $14.4 million in 2025, then advanced by 12.44% to $16.2 million in 2026.
- The last three Non-Current Assets figures came in at $16.2 million (Q1 2026), $14.4 million (Q4 2025), and $16.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 17.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.16 Mn |
| Mar 31, 2026 | 16.23 Mn |
| Dec 31, 2025 | 14.43 Mn |
| Sep 30, 2025 | 16.50 Mn |
| Jun 30, 2025 | 11.85 Mn |
| Mar 31, 2025 | 10.44 Mn |
| Dec 31, 2024 | 9.58 Mn |
| Sep 30, 2024 | 6.85 Mn |
| Jun 30, 2024 | 2.88 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 9.13 Mn |
| Sep 30, 2023 | 11.51 Mn |
| Jun 30, 2023 | 14.03 Mn |
| Mar 31, 2023 | 16.98 Mn |
| Dec 31, 2022 | 6.71 Mn |
| Sep 30, 2022 | 6.88 Mn |
| Jun 30, 2022 | 6.52 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Dec 31, 2021 | 5.36 Mn |
| Sep 30, 2021 | 9.46 Mn |